R&D News | pharmaphorum

News

Jean-François Toussaint, Sanofi's global head of vaccines R&D

FDA fast-tracks Sanofi's experimental chlamydia vaccine

Sanofi is preparing to start human testing of its chlamydia vaccine, now fast-tracked by the FDA, that it hopes will be the first to reach the market.

News

BIO rings alarm bells over Trump's pharma tariffs

US tariffs on goods coming from Europe, China, and Canada could have a major impact on the biopharma industry and medicines access, says BIO.

News

J&J throws the gauntlet down to AZ with new survival data

New survival data from MARIPOSA for Johnson & Johnson's Rybrevant/Lazcluze combination in lung cancer could spell trouble for AstraZeneca.

News

Character Bio chief executive and co-founder Cheng Zhang

Character raises $93m for eye drugs, plus other financings

Recent financings in the biotech space include rounds for Character Bio, Tempero, Epicrispr, Hillstar Bio, and Ampersand Biomedicines.

News

End of the line for Cassava's troubled Alzheimer's programme

The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end.

News

Drs Bhattacharya and Makary at Senate nomination hearings

Senate confirms Trump picks for FDA and NIH

The Senate has endorsed Martin Makary as FDA Commissioner and Jay Bhattacharya as NIH director, while Mehmet Oz moves closer to leading the CMS.

FDA fast-tracks Sanofi's experimental chlamydia vaccine

BIO rings alarm bells over Trump's pharma tariffs

J&J throws the gauntlet down to AZ with new survival data

Character raises $93m for eye drugs, plus other financings

End of the line for Cassava's troubled Alzheimer's programme

Senate confirms Trump picks for FDA and NIH

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks